We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 16, 2021

Effect of Empagliflozin on Cardiorenal Outcomes and Mortality According to BMI

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Effect of Empagliflozin on Cardiorenal Outcomes and Mortality According to Body-Mass Index: A Subgroup Analysis of the EMPA-REG OUTCOME Trial With a Focus on Asia
Diabetes Obes Metab 2021 May 05;[EPub Ahead of Print], Q Ji, L Ji, Y Mu, J Zhao, B Zinman, C Wanner, JT George, I Zwiener, K Ueki, K Yokote, W Ogawa, OE Johansen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading